{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:46:18Z","timestamp":1790707578509,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.ando.2014.04.012","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T08:15:58Z","timestamp":1404288958000},"page":"148-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hormonal prevention of breast cancer"],"prefix":"10.1016","volume":"75","author":[{"given":"Anne","family":"Thomin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Friszer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fajac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9mile","family":"Dara\u00ef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Chabbert-Buffet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ando.2014.04.012_bib0005","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bcp.2012.10.018","article-title":"Estrogen receptor signaling as a target for novel breast cancer therapeutics","volume":"85","author":"Renoir","year":"2013","journal-title":"Biochem Pharmacol"},{"issue":"5485","key":"10.1016\/j.ando.2014.04.012_bib0010","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1126\/science.289.5485.1751","article-title":"Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform","volume":"289","author":"Mulac-Jericevic","year":"2000","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ando.2014.04.012_bib0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1014820500738","article-title":"Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis","volume":"72","author":"Mote","year":"2002","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ando.2014.04.012_bib0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/gcc.10321","article-title":"Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A","volume":"39","author":"Mote","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.ando.2014.04.012_bib0025","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.4161\/cc.8.10.8406","article-title":"Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells","volume":"8","author":"Oliveras-Ferraros","year":"2009","journal-title":"Cell Cycle"},{"issue":"13","key":"10.1016\/j.ando.2014.04.012_bib0030","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/j.ejca.2010.06.012","article-title":"Metformin: taking away the candy for cancer?","volume":"46","author":"Jalving","year":"2010","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.ando.2014.04.012_bib0035","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.4161\/cc.8.16.9226","article-title":"Metformin, diet and breast cancer: an avenue for chemoprevention","volume":"8","author":"Muti","year":"2009","journal-title":"Cell Cycle"},{"issue":"8449","key":"10.1016\/j.ando.2014.04.012_bib0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0140-6736(85)90338-1","article-title":"Tamoxifen and contralateral breast cancer","volume":"326","author":"Cuzick","year":"1985","journal-title":"Lancet"},{"issue":"9114","key":"10.1016\/j.ando.2014.04.012_bib0045","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ando.2014.04.012_bib0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrc2048","article-title":"Chemoprevention of breast cancer with selective oestrogen-receptor modulators","volume":"7","author":"Jordan","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"9354","key":"10.1016\/j.ando.2014.04.012_bib0055","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breast-cancer prevention trials","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"issue":"9880","key":"10.1016\/j.ando.2014.04.012_bib0060","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ando.2014.04.012_bib0065","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","article-title":"Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis","volume":"28","author":"Ropka","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ando.2014.04.012_bib0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1677\/erc.1.00883","article-title":"Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA","volume":"13","author":"Labrie","year":"2006","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.ando.2014.04.012_bib0075","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/ncpendmet0559","article-title":"Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy","volume":"3","author":"Labrie","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"3\u20135","key":"10.1016\/j.ando.2014.04.012_bib0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0960-0760(03)00378-9","article-title":"Breast cancer prevention \u2013\u00a0clinical trials strategies involving aromatase inhibitors","volume":"86","author":"Goss","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4\u20136","key":"10.1016\/j.ando.2014.04.012_bib0085","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0960-0760(93)90270-7","article-title":"Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors","volume":"44","author":"Schieweck","year":"1993","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"19","key":"10.1016\/j.ando.2014.04.012_bib0090","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ando.2014.04.012_bib0095","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer","volume":"98","author":"Atac Trialists\u2019 Group","year":"2003","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.ando.2014.04.012_bib0100","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"The ATAC (Arimidex, T.A.o.i.C.T.G.)","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ando.2014.04.012_bib0105","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ando.2014.04.012_bib0110","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ando.2014.04.012_bib0115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10689-011-9484-4","article-title":"Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1\/2 mutations carriers: the LIBER trial","volume":"11","author":"Pujol","year":"2011","journal-title":"Fam Cancer"},{"issue":"1","key":"10.1016\/j.ando.2014.04.012_bib0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2012.06.015","article-title":"A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo \u2013\u00a0a substudy for IBIS I Breast Cancer Prevention Trial","volume":"49","author":"Palva","year":"2012","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ando.2014.04.012_bib0125","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/1055-9965.EPI-12-0201","article-title":"Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"21","author":"Kotsopoulos","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.ando.2014.04.012_bib0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ando.2014.04.012_bib0135","first-page":"491","article-title":"Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States)","volume":"5","author":"Schairer","year":"1994","journal-title":"Cancer Causes Control"},{"issue":"4","key":"10.1016\/j.ando.2014.04.012_bib0140","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/jnci\/92.4.328","article-title":"Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin","volume":"92","author":"Ross","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ando.2014.04.012_bib0145","first-page":"433","article-title":"Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses\u2019 Health Study","volume":"3","author":"Colditz","year":"1992","journal-title":"Cancer Causes Control"},{"issue":"3","key":"10.1016\/j.ando.2014.04.012_bib0150","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6","article-title":"Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy","volume":"81","author":"Magnusson","year":"1999","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.ando.2014.04.012_bib0155","first-page":"593","article-title":"Postmenopausal estrogen and progestin use in relation to breast cancer risk","volume":"11","author":"Newcomb","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.ando.2014.04.012_bib0160","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrc3518","article-title":"Progesterone signalling in breast cancer: a neglected hormone coming into the limelight","volume":"13","author":"Brisken","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"10\u201311","key":"10.1016\/j.ando.2014.04.012_bib0165","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0039-128X(00)00195-1","article-title":"Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer","volume":"65","author":"Klijn","year":"2000","journal-title":"Steroids"},{"issue":"1","key":"10.1016\/j.ando.2014.04.012_bib0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF01806133","article-title":"Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells","volume":"10","author":"Gill","year":"1987","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ando.2014.04.012_bib0175","first-page":"1441","article-title":"Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells","volume":"47","author":"Bardon","year":"1987","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ando.2014.04.012_bib0180","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/carcin\/23.5.749","article-title":"p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas","volume":"23","author":"Vanzulli","year":"2002","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.ando.2014.04.012_bib0185","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/carcin\/bgi060","article-title":"Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression","volume":"26","author":"Vanzulli","year":"2005","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.ando.2014.04.012_bib0210","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejca.2006.07.019","article-title":"Management of BRCA1\/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006","volume":"43","author":"Liebens","year":"2007","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ando.2014.04.012_bib0195","first-page":"455","article-title":"The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial","volume":"74","author":"Romieu","year":"1987","journal-title":"Bull Cancer"},{"issue":"7","key":"10.1016\/j.ando.2014.04.012_bib0200","first-page":"551","article-title":"Mifepristone. Auxiliary therapeutic use in cancer and related disorders","volume":"43","author":"Koide","year":"1998","journal-title":"J Reprod Med"},{"issue":"22","key":"10.1016\/j.ando.2014.04.012_bib0205","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1158\/1078-0432.CCR-12-3826","article-title":"Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer","volume":"19","author":"Skor","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"5804","key":"10.1016\/j.ando.2014.04.012_bib0190","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1126\/science.1130471","article-title":"Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist","volume":"314","author":"Poole","year":"2006","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ando.2014.04.012_bib0215","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-013-2722-8","article-title":"Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue","volume":"142","author":"Vilasco","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.ando.2014.04.012_bib0220","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/bjc.2012.414","article-title":"Diabetes and breast cancer risk: a meta-analysis","volume":"107","author":"Boyle","year":"2012","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ando.2014.04.012_bib0225","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/GME.0b013e31828ce95d","article-title":"Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis","volume":"20","author":"Esposito","year":"2013","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.ando.2014.04.012_bib0230","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1634\/theoncologist.2011-0462","article-title":"Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis","volume":"17","author":"Soranna","year":"2012","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ando.2014.04.012_bib0235","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10549-012-2170-x","article-title":"Metformin and breast cancer risk: a meta-analysis and critical literature review","volume":"135","author":"Col","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.ando.2014.04.012_bib0240","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.diabet.2012.06.003","article-title":"Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis","volume":"38","author":"Colmers","year":"2012","journal-title":"Diabetes Metab"},{"issue":"23","key":"10.1016\/j.ando.2014.04.012_bib0245","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2012.42.3319","article-title":"Diabetes, metformin, and breast cancer: lilac time?","volume":"30","author":"Goodwin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ando.2014.04.012_bib0250","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10549-012-2223-1","article-title":"Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study","volume":"135","author":"Niraula","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ando.2014.04.012_bib0255","article-title":"Recent insights into non-nuclear actions of estrogen receptor alpha","author":"Banerjee","year":"2013","journal-title":"Steroids"},{"issue":"10","key":"10.1016\/j.ando.2014.04.012_bib0260","doi-asserted-by":"crossref","first-page":"7169","DOI":"10.1074\/jbc.M111.292946","article-title":"Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-alpha36 (ERalpha36)","volume":"287","author":"Chaudhri","year":"2012","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ando.2014.04.012_bib0265","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/IGC.0b013e31827912b8","article-title":"The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K\/Akt pathway in endometrial cancer cells","volume":"23","author":"Ge","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10.1016\/j.ando.2014.04.012_bib0270","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.cellsig.2011.06.014","article-title":"Prolactin-stimulated activation of ERK1\/2 mitogen-activated protein kinases is controlled by PI3-kinase\/Rac\/PAK signaling pathway in breast cancer cells","volume":"23","author":"Aksamitiene","year":"2011","journal-title":"Cell Signal"},{"issue":"1","key":"10.1016\/j.ando.2014.04.012_bib0275","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/bcr2819","article-title":"Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer","volume":"13","author":"Arendt","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"12","key":"10.1016\/j.ando.2014.04.012_bib0280","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1051\/medsci\/201026121049","article-title":"Prolactin and its cleaved 16kDa fragment","volume":"26","author":"Lkhider","year":"2010","journal-title":"Med Sci (Paris)"},{"issue":"2","key":"10.1016\/j.ando.2014.04.012_bib0285","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/EJE-11-0076","article-title":"Cancer risk in hyperprolactinemia patients: a population-based cohort study","volume":"165","author":"Berinder","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.ando.2014.04.012_bib0290","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/carcin\/bgp120","article-title":"Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase","volume":"30","author":"LaPensee","year":"2009","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.ando.2014.04.012_bib0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-10-0069","article-title":"New concepts in prolactin biology","volume":"206","author":"Bernichtein","year":"2010","journal-title":"J Endocrinol"},{"issue":"6","key":"10.1016\/j.ando.2014.04.012_bib0300","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/jmedgenet-2012-101415","article-title":"Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1\/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium","volume":"50","author":"Fischer","year":"2013","journal-title":"J Med Genet"},{"key":"10.1016\/j.ando.2014.04.012_bib0305","series-title":"La pr\u00e9vention sanitaire","author":"Cour des Comptes","year":"2011"},{"issue":"6","key":"10.1016\/j.ando.2014.04.012_bib0310","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3111\/13696998.2012.713414","article-title":"Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France","volume":"15","author":"Laas","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.ando.2014.04.012_bib0315","series-title":"\u00c9tude nationale de co\u00fbts","author":"Agence technique de l\u2019information sur l\u2019hospitalisation","year":"2013"},{"issue":"21","key":"10.1016\/j.ando.2014.04.012_bib0320","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2005.03.3126","article-title":"Effect of chest X-rays on the risk of breast cancer among BRCA1\/2 mutation carriers in the international BRCA1\/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators\u2019 Group","volume":"24","author":"Andrieu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ando.2014.04.012_bib0325","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.ando.2014.04.012_bib0330","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2146\/ajhp100492","article-title":"Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer","volume":"68","author":"Gluck","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ando.2014.04.012_bib0335","series-title":"Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25mg vs. 100mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancer (study number NCT00555919)","author":"Bayer Study Director","year":"2011"},{"key":"10.1016\/j.ando.2014.04.012_bib0340","series-title":"Preoperative testing of the anti-progesterone mifepristone in early stage breast cancer","author":"McCarthy","year":"2013"},{"issue":"10","key":"10.1016\/j.ando.2014.04.012_bib0345","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ncpendmet0270","article-title":"Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?","volume":"2","author":"Goffin","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ando.2014.04.012_bib0350","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10911-008-9066-8","article-title":"Rational design of competitive prolactin\/growth hormone receptor antagonists","volume":"13","author":"Tallet","year":"2008","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"3","key":"10.1016\/j.ando.2014.04.012_bib0355","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/er.2004-0016","article-title":"Development and potential clinical uses of human prolactin receptor antagonists","volume":"26","author":"Goffin","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2014.04.012_bib0360","series-title":"Cabergoline in metastatic breast cancer (NCT01730729)","author":"Kaklamani","year":"2012"},{"key":"10.1016\/j.ando.2014.04.012_bib0365","first-page":"8","article-title":"Les scores de risque du cancer du sein","volume":"141","author":"Cohen-Haguenauer","year":"2009","journal-title":"Real Gynecol Obstet"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426614000651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426614000651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:47:15Z","timestamp":1757717235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426614000651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0003426614000651"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2014.04.012","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormonal prevention of breast cancer","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2014.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}